Dasiglucagon hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for dasiglucagon hydrochloride and what is the scope of freedom to operate?
Dasiglucagon hydrochloride
is the generic ingredient in two branded drugs marketed by Zealand Pharma and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Dasiglucagon hydrochloride has thirty-three patent family members in twenty-four countries.
Two suppliers are listed for this compound.
Summary for dasiglucagon hydrochloride
| International Patents: | 33 |
| US Patents: | 2 |
| Tradenames: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Clinical Trials: | 20 |
| DailyMed Link: | dasiglucagon hydrochloride at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for dasiglucagon hydrochloride
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for dasiglucagon hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Inreda Diabetic B.V. | Phase 2 |
| Filip Krag Knop | Phase 2 |
| Steno Diabetes Center Copenhagen | Phase 2 |
Pharmacology for dasiglucagon hydrochloride
| Drug Class | Antihypoglycemic Agent |
| Mechanism of Action | Glucagon Receptor Agonists |
| Physiological Effect | Increased Glycogenolysis |
Anatomical Therapeutic Chemical (ATC) Classes for dasiglucagon hydrochloride
US Patents and Regulatory Information for dasiglucagon hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zealand Pharma | ZEGALOGUE | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-001 | Mar 22, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Zealand Pharma | ZEGALOGUE (AUTOINJECTOR) | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-002 | Mar 22, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Zealand Pharma | ZEGALOGUE | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-001 | Mar 22, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Zealand Pharma | ZEGALOGUE (AUTOINJECTOR) | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-002 | Mar 22, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Zealand Pharma | ZEGALOGUE (AUTOINJECTOR) | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-002 | Mar 22, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Zealand Pharma | ZEGALOGUE | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-001 | Mar 22, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for dasiglucagon hydrochloride
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Poland | 2875043 | ⤷ Sign Up | |
| Eurasian Patent Organization | 201590058 | АНАЛОГИ ГЛЮКАГОНА | ⤷ Sign Up |
| Japan | 6534927 | ⤷ Sign Up | |
| Eurasian Patent Organization | 033399 | АНАЛОГИ ГЛЮКАГОНА С ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ И/ИЛИ СТАБИЛЬНОСТЬЮ И ИХ ПРИМЕНЕНИЕ (GLUCAGON ANALOGUES WITH INCREASED SOLUBILITY AND/OR STABILITY AND USE THEREOF) | ⤷ Sign Up |
| Spain | 2620111 | ⤷ Sign Up | |
| Argentina | 091866 | ANALOGOS DEL GLUCAGON | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
